Legal & General Group Plc decreased its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 11.4% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 13,163,028 shares of the company's stock after selling 1,685,978 shares during the period. Legal & General Group Plc owned 0.69% of Kenvue worth $281,031,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Kenvue during the fourth quarter worth $521,348,000. Franklin Resources Inc. lifted its position in Kenvue by 61.5% during the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after buying an additional 16,269,721 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in Kenvue by 12.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after buying an additional 10,682,003 shares during the last quarter. Boston Partners grew its holdings in Kenvue by 36.9% in the 4th quarter. Boston Partners now owns 23,595,963 shares of the company's stock valued at $503,145,000 after buying an additional 6,366,097 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Kenvue during the 4th quarter valued at about $98,926,000. Institutional investors and hedge funds own 97.64% of the company's stock.
Kenvue Stock Up 3.3 %
Shares of KVUE traded up $0.73 during mid-day trading on Monday, reaching $22.82. 2,177,512 shares of the stock traded hands, compared to its average volume of 16,861,854. The firm has a market cap of $43.61 billion, a price-to-earnings ratio of 43.06, a P/E/G ratio of 2.62 and a beta of 1.02. The stock has a fifty day simple moving average of $22.65 and a 200 day simple moving average of $22.40. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46.
Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.59%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's dividend payout ratio is currently 154.72%.
Analyst Ratings Changes
A number of research firms recently issued reports on KVUE. Citigroup lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a report on Wednesday, January 15th. Evercore ISI began coverage on shares of Kenvue in a research note on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective for the company. Canaccord Genuity Group increased their target price on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. UBS Group lowered their price target on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Finally, Barclays cut their price objective on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a report on Monday. Eight research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $24.35.
Read Our Latest Stock Analysis on KVUE
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
